Trials / Completed
CompletedNCT02629224
ASP8825 - Pharmacokinetics Study in Patients With Impaired Renal Function and Haemodialysis
Pharmacokinetic (PK) Study of ASP8825 - Evaluation of Pharmacokinetics in Patients With Impaired Renal Function and Haemodialysis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the pharmacokinetics and safety of ASP8825 in patients with impaired renal function and haemodialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASP8825 | Oral |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2015-12-14
- Last updated
- 2016-02-04
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02629224. Inclusion in this directory is not an endorsement.